Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.41 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841652 | 0.87 | RXRA (0.46) | P2RY14AKR1C3RXRARXRBJAK2 | |
| SCHEMBL19656312 | 0.86 | SCN10A (0.47) | AKR1C3RXRARXRBJAK2ADCY8 | |
| SCHEMBL29727643 | 0.85 | P2RY14 (0.49) | P2RY14JAK2TRPV1 | |
| SCHEMBL18285297 | 0.85 | P2RY14 (0.49) | P2RY14JAK2TRPV1 | |
| SCHEMBL18285347 | 0.85 | P2RY14 (0.49) | P2RY14MCHR1AKR1C3RXRARXRB | |
| SCHEMBL19656304 | 0.83 | ANO1 (0.51) | AKR1C3RXRARXRBJAK2 | |
| SCHEMBL15726944 | 0.82 | ADCY8 (0.46) | AKT1ADCY8ADCY1 | |
| SCHEMBL18285327 | 0.81 | P2RY14 (0.48) | P2RY14POLB | |
| SCHEMBL7753604 | 0.80 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL21841660 | 0.80 | HDAC1 (0.43) | POLBRXRARXRBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526201-B1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-11-18 | — | — | EP | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2018069362-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-19 | — | — | WO | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | P2RY14 855/4885POLB 4711/4885MCHR1 1084/4885 |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | P2RY14 855/4885POLB 4711/4885MCHR1 1084/4885 |
| US-10556870-B2 | Imidazole compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | P2RY14 2903/4885POLB 4615/4885MCHR1 906/4885 |
| US-20190233379-A1 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | P2RY14 2903/4885POLB 4615/4885MCHR1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.